Ubs Group Ag Regulus Therapeutics Inc. Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 90,147 shares of RGLS stock, worth $133,417. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90,147
Previous 29,876
201.74%
Holding current value
$133,417
Previous $46,000
208.7%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RGLS
# of Institutions
70Shares Held
53.5MCall Options Held
13.7KPut Options Held
7K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$19 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$9.57 Million0.73% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$7.4 Million1.54% of portfolio
-
Octagon Capital Advisors LP New York, NY4.85MShares$7.18 Million1.71% of portfolio
-
Black Rock Inc. New York, NY3.97MShares$5.87 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $21.7M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...